A recent meta-analysis on SGLT-2 treatment of NAFLD disease involving 850 overweight and obese individuals [10] found that SGLT-2 inhibitors significantly decreased liver enzymes and the absolute percentage of liver fat content, as assessed by magnetic resonance techniques. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.